| Treatment and dose | Patients# | Tumour | Subgroup | Correlation | Change during therapy | References | ||
| RR | PFS | OS | ||||||
| ABT-869 0.1 to 0.3 mg·kg−1·day−1 | 33 | Various | VEGF-A | ND | ND | ND | INC | 50 |
| Bevacizumab (15 mg·kg−1)+PC | 166/878 | NSCLC | VEGF-A <35.7 pg·mL−1 | NC | INC | NC | ND | 10 |
| E7080 1–40 mg·day−1 | 24 | Various | VEGF-A | ND | ND | ND | INC | 51 |
| GC±bevacizumab 15 mg·kg−1 | 56/108 | MM | VEGF-A <median | ND | INC | INC | ND | 52 |
| Vandetanib 300 mg·d−1 versus PC | 91/113 | NSCLC | VEGF-A >707 pg·mL−1 | ND | DEC (trend) | NC | ND | 13 |
| PC±vandetanib 300 mg·day−1 | 86/108 | NSCLC | VEGF-A <707 pg·mL−1 | ND | NC | NC | ND | 13 |
| Vandetanib 300 mg·day−1 versus gefitinib 250 mg·day−1 | 163/168 | NSCLC | Low VEGF-A <115 pg·mL−1 | ND | INC | ND | ND | 13 |
| Docetaxel±vandetanib 300 mg·day−1 | 45/85 | NSCLC | Low VEGF-A <115 pg·mL−1 | ND | NC | INC | ND | 13 |
| Docetaxel±vandetanib 100 mg | 44/83 | NSCLC | Low VEGF-A <115 pg·mL−1 | ND | INC | INC | ND | 13 |
| Pazopanib 800 mg q.o.d. | 19 | NSCLC | sVEGFR-2 | ND | ND | ND | DEC | 15 |
RR: response rate; PFS; progression-free survival; OS: overall survival; ABT-869: inhibitor of vascular endothelial growth factor receptors (VEGFR) 1–3 and platelet-derived growth factor receptors (PDGFR); Bevacizumab: VEGF antibody, receptor tyrosine kinase inhibitors; E7080: receptor tyrosine kinase inhibitors of VEGFR-2, PDGFRs, fibroblast growth factor receptors, c-kit; GC: gemcitabine and cisplatin; Vandetanib: antagonist of VEGFR-2, epidermal growth factor receptor, and inhibitor of RET; PC: paclitaxel and carboplatin; pazopanib: VEGFR, PDGFR and c-kit inhibitor; INC: increased/superior; DEC: decreased/inferior; ND: not determined; NC: no change; MM: malignant mesothelioma; NSCLC: nonsmall cell lung cancer. #: number of patients (or tumours) investigated/total number of patients.